- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01763567
Feasibility Study to Evaluate Safety and Device Performance of the Hospital Glucose Management System (HGMS) (MAHI)
A Multi-Phased, Multi-Center Study to Evaluate Safety and Device Performance of the Medtronic Hospital Glucose Management System (HGMS) in Critically Ill Adult Patients
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
Assess safety and device performance of the Medtronic HGMS in the critically-ill setting and analyze the following:
Device Performance:
- Functionality of HGMS
- Alerts/Alarms Specificity and Sensitivity
- System Workflow
Safety:
- Descriptive statistics will be used to characterize safety events
- Moderate and severe anticipated device and procedure related adverse events
- All serious adverse events and unanticipated adverse device effects related events
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
Missouri
-
Kansas City, Missouri, Vereinigte Staaten, 64111
- St Luke's Hospital Mid America Heart Institute
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Subject is at least 18 years old
- Subject is admitted to the ICU
- Subject has a treatment regimen that includes a glucose target range of ≥140 mg/dl
Subject has a treatment regimen that includes an intended continuous intravenous insulin for at least 24 hours
a. Including patients with no previous diagnosis of Diabetes Mellitus
- Subject has anticipated life expectancy greater than 96 hours
- Subject has recent platelet count greater than 30,000 per micro-liter
Exclusion Criteria:
- Subject currently has a suspected or diagnosed medical condition that, in the opinion of the Investigator, warrants exclusion from the study or prevents the subject from completing the study
- Subject is currently participating in another investigational drug or device study
- Subject is pregnant, as determined by hospital admission
- Subject is receiving treatment that includes Hydroxyurea.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Device Performance: Accuracy of HGMS
Zeitfenster: up to 72 hours
|
Mean Absolute Relative Difference (MARD), calculated as the absolute difference of [(sensor glucose values - iSTAT glucose values) / iSTAT glucose values]. The portable i-STAT handheld makes patient-side testing easy:
|
up to 72 hours
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Functionality of HGMS: Alerts and Alarms - % of Hypo Events Correctly Detected
Zeitfenster: up to 72 hours
|
The device alarmed within 30 minutes before or after the reference blood glucose value (i-STAT) goes below 70 mg/dL setting levels.
The % of hypo events correctly detected was calculated as: total number of correct events divided by total number of events from all 19 participants.
|
up to 72 hours
|
Functionality of HGMS: Alerts and Alarms - % of Hyper Events Correctly Detected
Zeitfenster: 72 hours
|
The device alarmed within 30 minutes before or after the reference blood glucose value (i-STAT) goes above 250 mg/dL setting levels.
The % of hyper events correctly detected was calculated as: total number of correct events divided by total number of events from all 19 participants.
|
72 hours
|
Functionality of HGMS: Alerts and Alarms - % of Hypo False Alert
Zeitfenster: Up to 72 hours
|
Definition of % of hypo false alert: within 30 minutes before or after the sensor alarmed at 70 mg/dL, there is no reference blood glucose value (i-STAT) that goes below 70 mg/dL.
The % of hypo false alert was calculated as: total number of false events divided by total number of events from all 19 participants.
NOTE: % of Hypo False Alert and % Hypo Event Correctly Detected do not necessarily add up to 100% because the denomintors are not the same.
|
Up to 72 hours
|
Functionality of HGMS: Alerts and Alarms - % of Hyper False Alert
Zeitfenster: Up to 72 hours
|
Definition of % of Hyper False Alert: within 30 minutes before or after the sensor alarmed at 250 mg/dL, there is no reference blood glucose value (i-STAT) that goes above 250mg/dL .
The % of hyper false alert was calculated as: total number of false events divided by total number of events from all 19 participants.
NOTE: % of Hyper False Alert and % Hyper Event Correctly Detected do not necessarily add up to 100% because the denomintors are not the same.
|
Up to 72 hours
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Mikhail Kosiborod, M.D, St Luke's Hospital - Mid America Heart Institute
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- CEP244
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .